Cargando…
ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasud...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648286/ https://www.ncbi.nlm.nih.gov/pubmed/37959203 http://dx.doi.org/10.3390/jcm12216736 |
_version_ | 1785135304414330880 |
---|---|
author | Pagano, Luca Lee, Jason William Posarelli, Matteo Giannaccare, Giuseppe Kaye, Stephen Borgia, Alfredo |
author_facet | Pagano, Luca Lee, Jason William Posarelli, Matteo Giannaccare, Giuseppe Kaye, Stephen Borgia, Alfredo |
author_sort | Pagano, Luca |
collection | PubMed |
description | Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects. |
format | Online Article Text |
id | pubmed-10648286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106482862023-10-25 ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs Pagano, Luca Lee, Jason William Posarelli, Matteo Giannaccare, Giuseppe Kaye, Stephen Borgia, Alfredo J Clin Med Review Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects. MDPI 2023-10-25 /pmc/articles/PMC10648286/ /pubmed/37959203 http://dx.doi.org/10.3390/jcm12216736 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pagano, Luca Lee, Jason William Posarelli, Matteo Giannaccare, Giuseppe Kaye, Stephen Borgia, Alfredo ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title | ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title_full | ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title_fullStr | ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title_full_unstemmed | ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title_short | ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs |
title_sort | rock inhibitors in corneal diseases and glaucoma—a comprehensive review of these emerging drugs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648286/ https://www.ncbi.nlm.nih.gov/pubmed/37959203 http://dx.doi.org/10.3390/jcm12216736 |
work_keys_str_mv | AT paganoluca rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs AT leejasonwilliam rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs AT posarellimatteo rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs AT giannaccaregiuseppe rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs AT kayestephen rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs AT borgiaalfredo rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs |